These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25313238)

  • 1. The imaging core lab perspective on glioblastoma imaging and response assessment in clinical trials.
    Goldmacher GV; Raunig D
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii48-50. PubMed ID: 25313238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of imaging measurements on response assessment in glioblastoma clinical trials.
    Reardon DA; Ballman KV; Buckner JC; Chang SM; Ellingson BM
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii24-35. PubMed ID: 25313236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
    Alexander BM; Wen PY; Trippa L; Reardon DA; Yung WK; Parmigiani G; Berry DA
    Neuro Oncol; 2013 Aug; 15(8):972-8. PubMed ID: 23857706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
    Delgado-López PD; Riñones-Mena E; Corrales-García EM
    Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
    Payer F
    Wien Med Wochenschr; 2011 Jan; 161(1-2):13-9. PubMed ID: 21312094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors.
    Srinivasan VM; Ene C; Kerrigan BP; Lang FF
    Neurosurg Clin N Am; 2021 Jan; 32(1):93-104. PubMed ID: 33223031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent and ongoing clinical trials in glioblastoma.
    Lombardi G
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):480-483. PubMed ID: 30067618
    [No Abstract]   [Full Text] [Related]  

  • 11. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas.
    Sanghera P; Rampling R; Haylock B; Jefferies S; McBain C; Rees JH; Soh C; Whittle IR
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):216-27. PubMed ID: 21783349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of early imaging response criteria in glioblastoma multiforme.
    Gladwish A; Koh ES; Hoisak J; Lockwood G; Millar BA; Mason W; Yu E; Laperriere NJ; Ménard C
    Radiat Oncol; 2011 Sep; 6():121. PubMed ID: 21943399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimaging: diagnosis and response assessment in glioblastoma.
    Clarke JL; Chang SM
    Cancer J; 2012; 18(1):26-31. PubMed ID: 22290254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult Glioblastoma.
    Alexander BM; Cloughesy TF
    J Clin Oncol; 2017 Jul; 35(21):2402-2409. PubMed ID: 28640706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
    Monaco EA; Tempel ZJ; Friedlander RM
    Neurosurgery; 2014 Aug; 75(2):N23-5. PubMed ID: 25033366
    [No Abstract]   [Full Text] [Related]  

  • 19. Glioblastoma in elderly patients.
    Coulter IC; Varma A; Kane PJ; Mukerji N
    J Neurosurg; 2014 May; 120(5):1246-7. PubMed ID: 24579663
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating glioblastoma patients with poor performance status: where do we go from here?
    Gállego Pérez-Larraya J; Ducray F
    CNS Oncol; 2014 May; 3(3):231-41. PubMed ID: 25055131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.